



Therapeutic Antibodies against Infectious Diseases

Guest Editor:

Dr. Hugues Fausther-Bovendo

1. Department of Microbiology and Immunology, Faculty of Medicine, CHU de Quebec and Laval University, Quebec City, QC G1V 4G2, Canada

2. Global Urgent and Advanced Research and Development, Batiscan City, QC G0X 1A0, Canada

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editor

Therapeutic antibodies have revolutionized modern medicines, notably the treatment of cancer, autoimmune disorders and infectious diseases. Despite their clinically proven efficacy, the use of therapeutic antibody is mainly limited to richer countries. Indeed, an estimated 80% of therapeutic antibodies are administered in North America and Europe alone.

The prohibitive costs of therapeutic antibodies and to a lower extent the need for intravenous administration have been hurdles to their wide-spread use. Various solutions are currently in pre-clinical phases of development. Notably, antibody gene therapy in which the nucleotide sequence of therapeutic antibodies, rather than proteins, are administered could help reduce the cost of antibody therapy. Sub-cutaneous formulation have also been developed to facilitate the administration of therapeutic antibodies.

This issue will focus on research encompassing novel therapeutic antibodies against infectious diseases. Submissions, on innovative work that could facilitate the broader use of therapeutic antibody globally, are also encouraged.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)